GH Research PLC
GHRSHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, GH Research PLC (GHRS) is listed under Biotechnology. The $1.97B market capitalization puts GHRS squarely in small-cap range for its industry. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Market Cap
$1.97B
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-14.36
EPS (TTM)
$-0.90
EPS (Fwd)
$-2.00
ROE
-19.7%
ROA
-14.0%
Cash
$267.3M
Total Debt
$432,000
Free CF
-$32.7M
52W Change
63.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $267.3M in cash comfortably exceeding the $432K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$32.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -19.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, GHRS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GHRS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.